# FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy

> **NCT00606528** · — · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 54 (actual)

## Conditions studied

- Chronic Hepatitis C Virus Infection

## Interventions

- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT00606528
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2013-07
- **Final completion:** —
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2013-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606528, "FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00606528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*